Drugs / Magicell-NK
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05394714 | Mar 2022 → Dec 2026 expected | colorectal cancer | Medigen Biotechnology Corporation | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06730009 | Oct 2024 → Jan 2029 expected | cholangiocarcinoma, exocrine pancreatic carcinoma | Medigen Biotechnology Corporation | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Magicell-NK | “Allogeneic Magicell-NK contains NK cells suspended in 100 mL of normal saline” NCT06730009 ↗ |
| Modality | Cell therapy | “Autologous ex Vivo Expanded and Activated NK Cell” NCT05394714 ↗ |
| Route | Other | “Magicell-NK, Infusion” NCT05394714 ↗ |